Frontline therapy of AML: Should the older patient be treated differently?

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Optimal treatment of acute myeloid leukemia (AML) in older adults (age ≥60 years) remains largely undefined, in part because of the inadequate response to available therapies, the poor prognosis relative to younger adults, the heterogeneity of the population, and the difficulty in determining who is fit for intensive therapy. In contrast to younger patients, there remains uncertainty about disease biology and molecular prognostic factors in elderly AML. While almost all patients may benefit from treatment, with the exception of reduced intensity allogeneic transplantation, there is little evidence that further intensifying therapy will improve outcomes. In fact, recent studies suggest that de-intensified treatment may in fact be superior and allow access to therapy for more patients. Both the disease and the patient must be approached holistically in order to make the best frontline treatment choice together. It is critical that we support well-designed clinical trials to develop more effective frontline therapies, develop more informative biomarkers, and to better understand who is a candidate for curative treatment.

Original languageEnglish (US)
Pages (from-to)100-108
Number of pages9
JournalCurrent Hematologic Malignancy Reports
Volume9
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Acute Myeloid Leukemia
Therapeutics
Homologous Transplantation
Population Characteristics
Uncertainty
Molecular Biology
Young Adult
Biomarkers
Clinical Trials

Keywords

  • Acute myeloid leukemia
  • De-intensified treatment
  • Elderly patients
  • Frontline therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Frontline therapy of AML : Should the older patient be treated differently? / Foran, James M.

In: Current Hematologic Malignancy Reports, Vol. 9, No. 2, 2014, p. 100-108.

Research output: Contribution to journalArticle

@article{08846a37b4744a1fb2ee5fcbd97ca802,
title = "Frontline therapy of AML: Should the older patient be treated differently?",
abstract = "Optimal treatment of acute myeloid leukemia (AML) in older adults (age ≥60 years) remains largely undefined, in part because of the inadequate response to available therapies, the poor prognosis relative to younger adults, the heterogeneity of the population, and the difficulty in determining who is fit for intensive therapy. In contrast to younger patients, there remains uncertainty about disease biology and molecular prognostic factors in elderly AML. While almost all patients may benefit from treatment, with the exception of reduced intensity allogeneic transplantation, there is little evidence that further intensifying therapy will improve outcomes. In fact, recent studies suggest that de-intensified treatment may in fact be superior and allow access to therapy for more patients. Both the disease and the patient must be approached holistically in order to make the best frontline treatment choice together. It is critical that we support well-designed clinical trials to develop more effective frontline therapies, develop more informative biomarkers, and to better understand who is a candidate for curative treatment.",
keywords = "Acute myeloid leukemia, De-intensified treatment, Elderly patients, Frontline therapy",
author = "Foran, {James M}",
year = "2014",
doi = "10.1007/s11899-014-0211-8",
language = "English (US)",
volume = "9",
pages = "100--108",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",
number = "2",

}

TY - JOUR

T1 - Frontline therapy of AML

T2 - Should the older patient be treated differently?

AU - Foran, James M

PY - 2014

Y1 - 2014

N2 - Optimal treatment of acute myeloid leukemia (AML) in older adults (age ≥60 years) remains largely undefined, in part because of the inadequate response to available therapies, the poor prognosis relative to younger adults, the heterogeneity of the population, and the difficulty in determining who is fit for intensive therapy. In contrast to younger patients, there remains uncertainty about disease biology and molecular prognostic factors in elderly AML. While almost all patients may benefit from treatment, with the exception of reduced intensity allogeneic transplantation, there is little evidence that further intensifying therapy will improve outcomes. In fact, recent studies suggest that de-intensified treatment may in fact be superior and allow access to therapy for more patients. Both the disease and the patient must be approached holistically in order to make the best frontline treatment choice together. It is critical that we support well-designed clinical trials to develop more effective frontline therapies, develop more informative biomarkers, and to better understand who is a candidate for curative treatment.

AB - Optimal treatment of acute myeloid leukemia (AML) in older adults (age ≥60 years) remains largely undefined, in part because of the inadequate response to available therapies, the poor prognosis relative to younger adults, the heterogeneity of the population, and the difficulty in determining who is fit for intensive therapy. In contrast to younger patients, there remains uncertainty about disease biology and molecular prognostic factors in elderly AML. While almost all patients may benefit from treatment, with the exception of reduced intensity allogeneic transplantation, there is little evidence that further intensifying therapy will improve outcomes. In fact, recent studies suggest that de-intensified treatment may in fact be superior and allow access to therapy for more patients. Both the disease and the patient must be approached holistically in order to make the best frontline treatment choice together. It is critical that we support well-designed clinical trials to develop more effective frontline therapies, develop more informative biomarkers, and to better understand who is a candidate for curative treatment.

KW - Acute myeloid leukemia

KW - De-intensified treatment

KW - Elderly patients

KW - Frontline therapy

UR - http://www.scopus.com/inward/record.url?scp=84903642930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903642930&partnerID=8YFLogxK

U2 - 10.1007/s11899-014-0211-8

DO - 10.1007/s11899-014-0211-8

M3 - Article

C2 - 24838493

AN - SCOPUS:84903642930

VL - 9

SP - 100

EP - 108

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

IS - 2

ER -